2 weeks Ago By Defense World Staff
Shares of INmune Bio, Inc. ( NASDAQ:INMB – Get Free Report ) traded up 1.7% during mid-day trading on Tuesday .
The company traded as high as $4.93 and last traded at $4.88.
131,907 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 165,580 shares. The stock had previously closed at $4.80.
Wall Street Analyst Weigh In A number of equities analysts recently issued reports on the stock. Scotiabank assumed coverage on shares of INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.
00 price target for the company. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.
00 price target for the company. Finally, Raymond James assumed coverage on shares of INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.
00 price target for the company. View Our Latest Report on INmune Bio INmune Bio Stock Up 1.7 % INmune Bio ( NASDAQ:INMB – Get Free Report ) last issued its earnings results on Thursday, October 31st.
The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.
11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.
59%. During the same quarter in the previous year, the firm posted ($0.48) earnings per share.
Equities research analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.
Insider Transactions at INmune Bio In related news, CEO Raymond Joseph Tesi purchased 15,380 shares of INmune Bio stock in a transaction on Thursday, September 12th. The shares were bought at an average cost of $6.38 per share, for a total transaction of $98,124.
40. Following the acquisition, the chief executive officer now owns 1,554,106 shares in the company, valued at approximately $9,915,196.28.
The trade was a 1.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink .
Also, CFO David J. Moss bought 7,690 shares of INmune Bio stock in a transaction dated Thursday, September 12th. The stock was acquired at an average price of $6.
38 per share, for a total transaction of $49,062.20. Following the completion of the acquisition, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.
22. The trade was a 0.61 % increase in their ownership of the stock.
The disclosure for this purchase can be found here . Insiders have acquired 33,070 shares of company stock worth $200,087 in the last 90 days. 35.
20% of the stock is currently owned by insiders. Hedge Funds Weigh In On INmune Bio A number of large investors have recently made changes to their positions in the company. Financial Advocates Investment Management boosted its position in INmune Bio by 17.
4% in the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after buying an additional 2,000 shares during the period. Jane Street Group LLC bought a new position in shares of INmune Bio during the 3rd quarter worth approximately $79,000.
Sanctuary Advisors LLC purchased a new position in shares of INmune Bio in the third quarter worth $113,000. Rhumbline Advisers purchased a new position in shares of INmune Bio in the second quarter worth $121,000. Finally, Barclays PLC raised its holdings in shares of INmune Bio by 601.
9% during the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after purchasing an additional 24,906 shares during the last quarter. 12.
72% of the stock is owned by hedge funds and other institutional investors. About INmune Bio ( Get Free Report ) INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Further Reading Five stocks we like better than INmune Bio 5 Top Rated Dividend Stocks to Consider Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor How to Use High Beta Stocks to Maximize Your Investing Profits Why Warren Buffett Is Selling: A Look at His Latest Market Moves Business Services Stocks Investing Why Amazon Shares May Never Trade Below $200 Again Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter ..
